SciTech Development, a clinical-stage oncology company dedicated to pioneering innovative nanotechnology-enabled cancer treatments, is thrilled to announce the successful closure of its third Convertible Note Round, known as CNR 3. This funding round, which officially concluded on September 5, 2025, achieved an impressive $5.5 million, significantly surpassing its initial target of $3.0 million by $2.5 million. This overwhelming investor confidence highlights the enthusiasm surrounding the company’s work.
The exceptional investor response is a direct reflection of the truly extraordinary interim results generated by SciTech’s flagship drug candidate, ST-001 nanoFenretinide. This innovative treatment, referred to as ST-001, is currently undergoing rigorous evaluation in clinical trials for T-cell Non-Hodgkin Lymphoma (T-cell NHL). These crucial trials are being conducted across nine highly respected cancer centers, underscoring the widespread interest and collaboration in advancing this potential therapy.
Recent updates from these clinical trials are particularly encouraging. ST-001 has achieved an unprecedented 100% Disease Control Rate at the highest dose levels administered thus far. This means that every patient treated at these levels has shown either stable disease, has experienced a partial response, or is clearly on a path toward achieving a complete response. Many patients have already experienced confirmed partial responses, a significant milestone that brings them closer to a potential complete recovery.
Furthermore, ST-001 nanoFenretinide has demonstrated its effectiveness in both early- and late-stage cancer patients, suggesting a broad therapeutic potential that could benefit a wide range of individuals battling this challenging disease. In addition to these documented positive clinical outcomes at therapeutic doses, the trial has also consistently confirmed the safety of ST-001.
This safety profile is a crucial validation of the robust scientific principles underlying the development of this drug. Notably, the majority of patients participating in the trial have reported only minimal side effects. This positive experience, coupled with noticeable improvements in their health and overall quality of life, has led most patients to willingly continue their participation in the trial, further emphasizing the drug’s positive impact.
KEY QUOTES:
“This has truly been a breakout year for SciTech. The oversubscription of our CNR 3 underscores the confidence investors place in our science, our market position, and the transformative potential of ST-001. We are deeply grateful to both new and returning investors for their belief in our mission and support as we advance into the next phase of our trials.”
Earle Holsapple, CEO of SciTech Development
“Our new and returning investors are motivated by the exceptional interim trial results we’ve delivered and the proven strength of our team. This investment enables us to continue to advance clinical development in both T-cell NHL and Small Cell Lung Cancer, while building a strong foundation for our future pipeline.”
Andrew Stumpf, CFO of SciTech Development
